According to Zacks, “Yield10 Bioscience, Inc. is an agricultural bioscience company. It focuses on the development of disruptive technologies for improvement in crop yield to enhance global food security. The company is working on new approaches, to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism for better production. It operates primarily in Saskatoon, Saskatchewan, Canada. Yield10 Bioscience, Inc., formerly known as Metabolix, Inc., is based in Woburn, Massachusetts. “
YTEN has been the topic of a number of other reports. National Securities restated a “hold” rating and set a $10.00 price target on shares of Yield10 Bioscience in a research report on Friday, May 15th. Maxim Group restated a “buy” rating and set a $12.00 price target on shares of Yield10 Bioscience in a research report on Thursday, August 13th.
Shares of YTEN stock traded up $0.06 during trading hours on Thursday, hitting $4.40. The company had a trading volume of 15,771 shares, compared to its average volume of 204,895. Yield10 Bioscience has a 12 month low of $3.50 and a 12 month high of $37.62. The firm’s fifty day moving average is $6.06 and its 200 day moving average is $5.84. The company has a current ratio of 6.15, a quick ratio of 6.15 and a debt-to-equity ratio of 0.40.
Yield10 Bioscience (NASDAQ:YTEN) last released its quarterly earnings data on Tuesday, August 11th. The specialty chemicals company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($1.30) by $0.38. Yield10 Bioscience had a negative return on equity of 347.89% and a negative net margin of 1,861.39%. Equities analysts anticipate that Yield10 Bioscience will post -5.05 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in Yield10 Bioscience stock. Virtu Financial LLC bought a new stake in Yield10 Bioscience Inc (NASDAQ:YTEN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,246 shares of the specialty chemicals company’s stock, valued at approximately $64,000. Virtu Financial LLC owned 0.52% of Yield10 Bioscience at the end of the most recent quarter. Institutional investors own 5.76% of the company’s stock.
Yield10 Bioscience Company Profile
Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield.
Featured Story: How Do Front-End Loads Impact an Investment?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.